Compare Crispr Therapeutics AG (CRSP) vs ProShares UltraPro S&P500 (UPRO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs ProShares UltraPro S&P500 — how do they compare? Crispr Therapeutics AG trades at $53.85 (market cap $5.23B), while ProShares UltraPro S&P500 trades at $154.28. The key difference: ProShares UltraPro S&P500 is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CRSP | UPRO | |
|---|---|---|
Market Cap | $5.23B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $76.78 | $155.10 |
52-Week Low | $44.34 | $89.29 |
Enterprise Value | $3.65B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
UPRO trades at $154.38, down 0.39% on the day, while maintaining a bullish technical outlook with strong moving average signals. The leveraged ETF tracking the S&P 500 faces mixed sentiment as oscillators show neutral readings amid record market highs. Recent institutional activity includes Bay Colony Advisors establishing a new position, indicating professional interest despite valuation concerns in the broader market.
The ETF's performance remains tied to S&P 500 momentum, with technical strength supporting near-term upside potential. However, elevated RSI levels and market-wide valuation concerns present headwinds. The absence of traditional fundamental metrics for this leveraged product emphasizes its tactical rather than long-term investment nature.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About ProShares UltraPro S&P500
UPRO is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to three times (3x) the daily performance of the S&P 500 Index. It is a tactical, high-conviction instrument designed for short-term traders to amplify bullish market moves, utilizing a daily reset mechanism that creates significant compounding effects and volatility risks over time.
Read more on UPRO →
